Andrew Cheng - 01 Jun 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President and CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
01 Jun 2023
Net transactions value
-$1,090,971
Form type
4
Filing time
05 Jun 2023, 18:23:55 UTC
Previous filing
12 May 2023
Next filing
15 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $13,118 +21,330 +5.2% $0.6150* 430,623 01 Jun 2023 Direct F1
transaction AKRO Common Stock Options Exercise $23,341 +3,670 +0.85% $6.36* 434,293 01 Jun 2023 Direct F1
transaction AKRO Common Stock Sale $172,902 -3,914 -0.9% $44.18 430,379 01 Jun 2023 Direct F1, F2
transaction AKRO Common Stock Sale $936,170 -20,686 -4.8% $45.26 409,693 01 Jun 2023 Direct F1, F3
transaction AKRO Common Stock Sale $18,359 -400 -0.1% $45.90 409,293 01 Jun 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -21,330 -25% $0.000000 64,538 01 Jun 2023 Common Stock 21,330 $0.6150 Direct F1, F5
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -3,670 -2.6% $0.000000 140,000 01 Jun 2023 Common Stock 3,670 $6.36 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.72 to $44.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.74 to $45.72, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.795 to $45.99, inclusive.
F5 The options are vested and currently exercisable.